Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2004

01-02-2004 | Review Article

Drug-Induced Renal Calculi

Epidemiology, Prevention and Management

Authors: Dr Michel Daudon, Paul Jungers

Published in: Drugs | Issue 3/2004

Login to get access

Abstract

Drug-induced calculi represent 1–2% of all renal calculi. The drugs reported to produce calculi formation may be divided into two groups.
The first one includes poorly soluble drugs with high urine excretion that favours crystallisation in the urine. Among poorly soluble molecules, triamterene was the leading cause of drug-containing urinary calculi in the 1970s, and it is still currently responsible for a significant number of calculi. In the last decade, drugs used for the treatment of HIV-infected patients, namely indinavir and sulfadiazine, have become the most frequent cause of drug-containing urinary calculi. Besides these drugs, about twenty other molecules may induce nephrolithiasis in patients receiving long-term treatment or high doses. Calculi analysis by physical methods, including infrared spectroscopy or x-ray diffraction, is needed to demonstrate the presence of the drug or its metabolites within the calculi.
The second group includes drugs that provoke urinary calculi as a consequence of their metabolic effects. Here, diagnosis relies on careful clinical inquiry because physical methods are ineffective to differentiate between urinary calculi induced by the metabolic effects of a drug and common metabolic calculi. The incidence of such calculi, especially those resulting from calcium/vitamin D supplementation, is probably underestimated.
Although drug-induced urinary calculi most often complicate high-dose, long-duration drug treatments, there also exist specific patient risk factors in relation to urine pH, urine output and other parameters, which provide a basis for preventive or curative treatment of calculi.
Better awareness of the possible occurrence of lithogenic complications, preventive measures based on drug solubility characteristics and close surveillance of patients on long-term treatment with drugs with lithogenic potential, especially those with a history of urolithiasis, should reduce the incidence of drug-induced nephrolithiasis.
Footnotes
1
The use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Antopol W, Robinson H. Urolithiasis and renal pathology after administration of sulfapyridine. Proc Soc Exp Biol Med 1939; 40: 428–39
2.
Barnes RW, Kawaichi GK. Factors influencing the formation of sulfonamide urinary concretions. J Urol 1943; 49: 324–30
3.
Sulfamidothérapie intestinale. In: Abaza A. Acquisitions médicales récentes dans les pays alliés. Paris: Doin & Cie, 1946: 260–83
4.
Lawrence JS, Francis J, Sorsby A, et al. The sulphonamides and antibiotics in man and animals. London: Lewis HK & Co Ltd, 1953
5.
6.
7.
Daudon M, Protat MF, Réveillaud RJ. Detection and diagnosis of drug-induced urinary calculi [in French]. Ann Biol Clin (Paris) 1983; 41(4): 239–49
8.
Réveillaud RJ, Daudon M. Drug-induced urinary lithiasis [in French]. Presse Med 1983; 12(38): 2389–92PubMed
9.
Cifuentes Delatte L. Composicion y estructura de los calculos renales. Madrid: Salvat, 1984
10.
Daudon M, Réveillaud RJ. Drug nephrolithiasis: an unrecognized and underestimated pathology. In: Schwille PO, Smith LH, Robertson WG, et al., editors. Urolithiasis and related clinical Research. New York: Plenum Press, 1985: 371–4CrossRef
11.
Réveillaud RJ, Daudon M. Les lithiases urinaires médicamenteuses. Semin Uro-Nephrol 1986; 12: 14–39
12.
Rapado A, Traba ML, Caycho C, et al. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol 1987; 58: 25–9PubMed
13.
Daudon M, Estepa L. Drug induced lithiases [in French]. Presse Med 1998; 27(14): 675–83PubMed
14.
Daudon M. Drug-induced urinary calculi in 1999 [in French]. Prog Urol 1999; 9(6): 1023–33PubMed
15.
Watson RA, Ettinger B, Deshon Jr GE, et al. Triamterene stone: advantage of crystallographic analysis. Urology 1981; 18(3): 238–40PubMedCrossRef
16.
Daudon M, Bader CA, Jungers P. Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc 1993; 7: 1081–106PubMed
17.
Nguyen Quy D, Daudon M. Infrared and raman spectra of calculi. Paris: Elsevier, 1997
18.
Daudon M, Réveillaud RJ. Drug-induced crystalluria: myths and realities [in French]. Ann Biol Clin 1986; 44(1): 25–34
19.
Daudon M. Méthodes d’analyse des calculs et des cristaux urinaires: classification morpho-constitutionnelle des calculs. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences, 1989: 35–113
20.
21.
Gagnon RF, Tsoukas CM, Watters AK. Light microscopy of indinavir urinary crystals [letter]. Ann Intern Med 1998; 128(4): 321PubMed
22.
Cohen-Solal F, Abdelmoula J, Hoarau MP, et al. Urinary lithiasis of medical origin [in French]. Therapie 2001; 56(6): 743–50PubMed
23.
Daudon M, Réveillaud RJ, Normand M, et al. Piridoxilateinduced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis. J Urol 1987; 138(2): 258–61PubMed
24.
25.
Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem 1986; 24: 767–8
26.
Ettinger B, Weil E, Mandel NS, et al. Triamterene-induced nephrolithiasis. Ann Intern Med 1979; 91(5): 745–6PubMed
27.
Socolow EL. Triamterene-induced nephrolithiasis [letter]. Ann Intern Med 1980; 92(3): 437PubMed
28.
Baudin S, Rodrigue H. Drug induced nephrolithiasis: observation of an oxalate and hydroxylated triamterene stone [in French]. Néphrologie 1980; 1(4): 183–5PubMed
29.
Gault MH, Snedden W, Taor RE, et al. Triamterene urolithiasis. CMAJ 1981; 124(12): 1556–7
30.
31.
Daudon M, Protat MF, Réveillaud RJ. Triamterene and renal calculi [in French]. Néphrologie 1982; 3(3): 119–23PubMed
32.
Moesch C, Rincé M, Raby C, et al. Analysis of triamterene induced renal stones [in French]. J Pharm Clin 1989; 18: 87–95
33.
Carey RA, Beg MM, McNally CF, et al. Triamterene and renal lithiasis: a review. Clin Ther 1984; 6(3): 302–9PubMed
34.
35.
36.
Carr MC, Prien Jr EL, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144(6): 1339–40PubMed
37.
Sorgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol 1985; 134(5): 871–3PubMed
38.
Sabot JF, Bernard P, Pinatel H, et al. Analysis of urinary calculi containing triamterene: presence of a glucuronic metabolite. Anal Lett 1996, 27
39.
Pruitt A, Winkel J, Dayton P. Variations in the fate of triamterene. Clin Pharmacol Ther 1977; 21: 610–9PubMed
40.
Sorgel F, Ettinger B, Benet LZ. Metabolic fate and solubility of triamterene: not an explanation for triamterene nephrolithiasis. J Pharm Sci 1986; 75(2): 129–32PubMedCrossRef
41.
Fairley KF, Birch DF, Haines I. Abnormal urinary sediment in patients on triamterene. Lancet 1983; I: 421–2CrossRef
42.
Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylindruria: clinical and experimental studies. Clin Nephrol 1986; 26: 169–73PubMed
43.
Farge D, Turner MW, Roy DR, et al. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition. Am J Kidney Dis 1986; 8(6): 445–9PubMed
44.
Roy LF, Villeneuve JP, Dumont A, et al. Irreversible renal failure associated with triamterene. Am J Nephrol 1991; 11: 486–8PubMedCrossRef
45.
Jick H, Dinan BJ, Hunter JR. Triamterene and renal stones. J Urol 1982; 127(2): 224–5PubMed
46.
Ettinger B. Excretion of triamterene and its metabolite in triamterene stone patients. J Clin Pharmacol 1985; 25(5): 365–8PubMed
47.
Kau S. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther 1978; 206: 701–9PubMed
48.
49.
Jungers P, Daudon M. Formes cliniques de la lithiase urinaire: lithiases médicamenteuses. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences, 1989: 408–16
50.
White DJ, Nancollas GH. Triamterene and renal stone formation. J Urol 1982; 127(3): 593–7PubMed
51.
Werness PG, Bergert JH, Smith LH. Triamterene urolithiasis: solubility, pk, effect on crystal formation, and matrix binding of triamterene and its metabolites. J Lab Clin Med 1982; 99(2): 254–62PubMed
52.
Lynn K, Bailey R, Swainson C, et al. Renal failure with potassium-sparing diuretics. N Z Med J 1985; 98: 629–33PubMed
53.
Favre L, Glasson P, Valotton M. Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med 1982; 96: 317–20PubMed
54.
Weinberg M, Quigg R, Salant D, et al. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40: 216–8PubMedCrossRef
55.
Estepa-Maurice L, Hennequin C, Marfisi C, et al. Fourier transform infrared microscopy identification of crystal deposits in tissues: clinical importance in various pathologies. Am J Clin Pathol 1996; 105: 576–82PubMed
56.
Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet 1985; II(8446): 73–5CrossRef
57.
Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124(12): 1086–8PubMed
58.
Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277(2): 145–53PubMedCrossRef
59.
European Agency for the Evaluation of Medicinal Products. Commission decision of 4 October 1996 granting the marketing authorization for the medicinal product for human use, ‘CRIXIVAN® — Indinavir’. London: European Agency for the Evaluation of Medicinal Products, 1996
60.
Merck & Co. Crixivan (indinavir sulphate) [Product monograph]. West Point (PA): Merck & Co., 1997
61.
Herman JS, Ives NJ, Nelson M, et al. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001; 48(3): 355–60PubMedCrossRef
62.
Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119–25PubMed
63.
Hermieu JF, Prevot MH, Ravery V, et al. Nephritic colic due to indinavir [in French]. Presse Med 1998; 27(10): 465–7PubMed
64.
Piroth L, Grappin M, Waldner A, et al. Discontinuation of protease inhibitors due to intolerance: a longitudinal study in 309 HIV-1 positive patients [in French]. Presse Med 1999; 28(8): 381–7PubMed
65.
Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS 1998; 12(18): F249–54PubMedCrossRef
66.
Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999; 161(4): 1082–4PubMedCrossRef
67.
Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133(1): 35–9PubMed
68.
Saltel E, Angel JB, Futter NG, et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 2000; 164(6): 1895–7PubMedCrossRef
69.
Hermieu J, Prevot M, Ravery V, et al. Urolithiasis and the protease inhibitor indinavir. Eur Urol 1999; 35(3): 239–41PubMedCrossRef
70.
Gentle DL, Stoller ML, Jarrett TW, et al. Protease inhibitor-induced urolithiasis. Urology 1997; 50(4): 508–11PubMedCrossRef
71.
Sundaram CP, Saltzman B. Urolithiasis associated with protease inhibitors. J Endourol 1999; 13(4): 309–12PubMedCrossRef
72.
Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 1999; 161(6): 1765–8PubMedCrossRef
73.
Blake SP, McNicholas MMJ, Raptopoulos V. Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. AJR Am J Roentgenol 1998; 171(3): 717–20PubMed
74.
Schwartz BF, Schenkman N, Armenakas NA, et al. Imaging characteristics of indinavir calculi. J Urol 1999; 161(4): 1085–7PubMedCrossRef
75.
76.
Kopp JB, Falloon J, Fili A, et al. Indinavir-associated with interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002; 34(8): 1122–8PubMedCrossRef
77.
Van Glabeke E, Conort P, Chartier-Kastler E, et al. Treatment of complicated renal colic in patients treated with indinavir: value of double J stents [in French]. Prog Urol 1999; 9(3): 470–3PubMed
78.
Martinez E, Leguizamon M, Mallolas J, et al. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin infect Dis 1999; 29(2): 422–5PubMedCrossRef
79.
Bach MC, Godofski EW. Indinavir nephrolithiasis in warm climates. J AIDS Hum Pathol 1997; 14: 296–7
80.
81.
van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS 2001; 15(13): 1745–7PubMedCrossRef
82.
Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001; 38(4): E23PubMedCrossRef
83.
Berns JS, Cohen RM, Silverman M, et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997; 30(4): 558–60PubMedCrossRef
84.
Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13(3): 750–3PubMedCrossRef
85.
Grabe DW, Eisele G, Miller C, et al. Indinavir-induced nephropathy. Clin Nephrol 1999; 51(3): 181–3PubMed
86.
Jaradat M, Phillips C, Yum MN, et al. Acute tubulointerstitial nephritis attributable to indinavir therapy [letter]. Am J Kidney Dis 2000; 35(4): E16PubMedCrossRef
87.
Anglicheau D, Duvic C, Nedelec G. Sudden anuria due to indinavir crystalluria. Nephron 2000; 86(3): 364–5PubMedCrossRef
88.
Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54(4): 261–70PubMed
89.
Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998; 50: 194–6PubMed
90.
van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir [letter]. Pediatrics 2002; 110 (2 Pt 1): e19PubMedCrossRef
91.
Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349(9061): 1294–5PubMedCrossRef
92.
Balani SH, Arison BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23: 266–70PubMed
93.
Chen IW, Vastag KJ, Lin JH. High-performance liquid Chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatogr B Biomed Appl 1995; 672: 111–7PubMedCrossRef
94.
Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42(2): 332–8PubMed
95.
Hortin GL, King C, Miller KD, et al. Detection of indinavir crystals in urine: dependence on method of analysis. Arch Pathol Lab Med 2000; 124(2): 246–50PubMed
96.
Rickerts V, Kober A, Stille W. Kristallurie und Nephrolithiasis bei Therapie mit dem Protease-Inhibitor Indinavir [letter]. Dtsch Med Wochenschr 1997; 122(24): 803PubMed
97.
Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000; 36(3): 507–15PubMedCrossRef
98.
Daudon M, Estepa L, Viard JP, et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers AL, Hibbert BE, Hess B, et al., editors. Urolithiasis 2000. Vol. I. Rondebosh: University of Cape Town, 2000: 335–7
99.
Daudon M, Estepa L, Viard JP, et al. Épidémiologie et facteurs de risque des complications lithiasiques de l’indinavir. Feuill Biol 2001; 42(242): 31–4
100.
Famularo G, Di Toro S, Moretti S, et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000; 34(12): 1414–8PubMedCrossRef
101.
Daudon M, Estepa L, Kebede M, et al. Urinary calculi and crystalluria in HIV+ patients treated with indinavir sulfate [in French]. Presse Med 1997; 26(34): 1612–5PubMed
102.
Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 1999; 340(5): 392–3PubMedCrossRef
103.
Brodie SB, Keller MJ, Ewenstein BM, et al. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998; 12(18): 2433–7PubMedCrossRef
104.
Ascher DP, Lucy MD. Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection. Ann Pharmacother 1997; 31(10): 1146–9PubMed
105.
Malavaud B, Dinh B, Bonnet E, et al. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000; 5(1): 3–5PubMed
106.
Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162(13): 1493–501PubMedCrossRef
107.
Meraviglia P, Angeli E, Del Sorbo F, et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS 2002; 16(15): 2089–93PubMedCrossRef
108.
Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13(4): 473–8PubMedCrossRef
109.
Rebassa Llull MJ, Conte Visus A, Grases Freixedas F, et al. Anuria in HIV+ patients treated with indinavir [in Spanish]. Arch Esp Urol 2000; 53(8): 719–21PubMed
110.
Kalaitzis C, Dimitriadis G, Tsatidis T, et al. Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients. Int Urol Nephrol 2002; 34(1): 13–5PubMedCrossRef
111.
112.
Grases F, Costa-Bauza A, Garcia-Gonzalez R, et al. Indinavir crystallization and urolithiasis. Int Urol Nephrol 1999; 31(1): 23–9PubMedCrossRef
113.
Verdon R, Daudon M, Albessard F, et al. Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 2002; 35(5): e57–9PubMedCrossRef
114.
Burger DM, Hugen PW, Aamoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001; 26(3): 218–24PubMedCrossRef
115.
116.
Trolliet P, Dijoud F, Cotte L, et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol 1995; 15: 256–9PubMedCrossRef
117.
Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32(3): 392–400PubMedCrossRef
118.
Peterslund NA, Larsen ML, Mygind H. Acyclovir crystalluria. Scand J Infect Dis 1988; 20(2): 225–8PubMedCrossRef
119.
Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure: clinical course and histology. Am J Med 1988; 84(6): 1067–71PubMedCrossRef
120.
Bianchetti MG, Roduit C, Oetliker OH. Acyclovir-induced renal failure: course and risk factors. Pediatr Nephrol 1991; 5: 238–9PubMedCrossRef
121.
Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 1993; 22: 611–5PubMed
122.
Fogazzi GB. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant 1996; 11(2): 379–87PubMedCrossRef
123.
Newman HR, Shleser IH. Sulfonamide renal calculus. J Urol 1942; 47: 258–9
124.
125.
Albala DM, Prien Jr EL, Galal HA. Urolithiasis as a hazard of sulfonamide therapy. J Endourol 1994; 8(6): 401–3PubMedCrossRef
126.
Diaz F, Collazos J, Mayo J,et al. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacother 1996; 30(1): 41–2PubMed
127.
Goadsby PJ, Donaghy AJ, Lloyd AR, et al. Acquired immunodeficiency syndrome (AIDS) and s0ulfadiazine-associated acute renal failure. Ann Intern Med 1987; 107(5): 783–4PubMed
128.
Sahai J, Heimberger T, Collins K, et al. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am J Med 1988; 84(4): 791–2PubMedCrossRef
129.
Christin S, Baumelou A, Bahri S, et al. Acute renal failure due to sulfadiazine in patients with AIDS. Nephron 1990; 55(2): 233–4PubMedCrossRef
130.
Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993; 39(5): 254–6PubMed
131.
Kronawitter U, Jakob K, Zoller WG, et al. Acute kidney failure caused by sulfadiazine stones: a complication of the therapy of toxoplasmosis in AIDS [in German]. Dtsch Med Wochenschr 1993; 118(46): 1683–6PubMedCrossRef
132.
Marques LP, Madeira EP, Santos OR. Renal alterations induced by sulfadiazine therapy in an AIDS patients. Clin Nephrol 1994; 42(1): 68–9PubMed
133.
Furrer H, von Overbeck J, Jaeger P, et al. Sulfadiazine nephrolithiasis and nephropathy [in German]. Schweiz Med Wochenschr 1994; 124(46): 2100–5PubMed
134.
Potter JL, Kofron WG. Sulfadiazine/N4-acetylsulfadiazine crystalluria in a patient with the acquired immune deficiency syndrome (AIDS). Clin Chim Acta 1994; 230(2): 221–4PubMedCrossRef
135.
Farina LA, Palou Redorta J, Chechile Toniolo G. Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient. Arch Esp Urol 1995; 48(4): 418–9PubMed
136.
Rodriguez-Carballeira M, Casagran A, More J, et al. Acute renal insufficiency caused by a sulfadiazine in a patient with cerebral toxoplasmosis and AIDS [in Spanish]. Enferm Infecc Microbiol Clin 1996; 14(2): 125–7PubMed
137.
Crespo M, Quereda C, Pascual J, et al. Patterns of sulfadiazine acute nephrotoxicity. Clin Nephrol 2000; 54(1): 68–72PubMed
138.
Sillar DB, Kleinig D. Sulphur calculi from ingestion of sulphasalazine. Br J Urol 1993; 71(6): 750–1PubMedCrossRef
139.
Erturk E, Casemento JB, Guertin KR, et al. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 1994; 151(6): 1605–6PubMed
140.
Yanagisawa R, Kamijo T, Nagase Y. A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis [in Japanese]. Nippon Hinyokika Gakkai Zasshi 1999; 90(3): 462–5PubMed
141.
Russinko PJ, Agarwal S, Choi MJ, et al. Obstructive nephropathy secondary to sulfasalazine calculi. Urology 2003; 62(4): 748PubMedCrossRef
142.
Dorfman LE, Smith JP. Sulfonamide crystalluria: a forgotten disease. J Urol 1970; 104(3): 482–3PubMed
143.
Daudon M, Protat MF, Réveillaud RJ, et al. Study of spontaneous crystalluria by infrared spectroscopy: search for correlations between crystals, calculi, bacteria and the sex of the patients [in French]. Ann Biol Clin (Paris) 1983; 41: 199–207
144.
Siegel WH. Unusual complication of therapy with sulfamethoxazole-trimethoprim. J Urol 1977; 117(3): 397PubMed
145.
Karcher G, Tammen H, Martin C. Healing of a chronic therapyresistant urinary tract infection, complicated by bladder calculi and bladder inflow obstruction with Bactrim. Case report [in German]. Med Welt 1972; 23(39): 1363–4PubMed
146.
Bülow H, Klee WE, Hotzel A, et al. Zur Frage einer Harnsteinbildung nach Trimethoprim Sulfamethoxazol-Therapie. Fortsch Urol Nephrol 1977; 9: 116–9CrossRef
147.
Bulkova T, Kladensky J, Pacik D, et al. Drug-induced urolithiasis caused by N4-acetylsulfamethoxazole (Biseptol) and oxolinic acid (Desurol) [in Czech]. Rozhl Chir 1992; 71(11): 615–23PubMed
148.
Rincé M, Dudognon P, Moesch C, et al. Urinary lithiasis induced by sulfamethoxazole in a patient with tetraplegia: case report. Paraplegia 1992; 30(10): 750–1PubMedCrossRef
149.
Otto H, Allesch V. Urinary concrements due to long-term sulfonamides [in German]. Urologe 1969; 8(4): 202–4PubMed
150.
Neal Jr MP. General case of the day. Sulfonamide crystallization in nonalkalinized urine. Radiographics 1988; 8(5): 993–6PubMed
151.
Whiting F, Connell R, Forman SA. Silica urolithiasis in beef cattle: the incidence on different rations and on range. Can J Comp Med Vet Sci 1958; 22: 332–7PubMed
152.
Daudon M, Estepa L, Labro B, et al. Infrared analysis of urinary calculi from animals [in French]. Eurobiol 1998; 236: 243–55
153.
Hammarsten G, Helldorff I, Magnusson W, et al. Dubbelsidiga njurstenar av kiselsyra efter bruk av silikathaltigt antacidum. Svensk Lakartiduing 1953; 50: 1242–6
154.
Hammarsten G. Terapi-inducerade urinvOagskonkrement. Opusc Med 1958; 3(1): 19–22
155.
Herman JR, Goldberg AS. New type of urinary calculus caused by antacid therapy. JAMA 1960 Oct; 174: 1206–7PubMedCrossRef
156.
Lagergren C. Development of silica calculi after oral administration of magnesium trisilicate. J Urol 1962; 87(6): 994–6PubMed
157.
Lipworth E, Bloomberg BM, Reid FP. Urinary calculi containing silica: a case report. S Afr Med J 1964; 50(1): 50–1
158.
159.
Medina JA, Rodriguez J, Santos M, et al. Siliceous renal calculi in a man (11th case in the world) [in Spanish]. Rev Clin Esp 1978; 151(5): 411–3PubMed
160.
Levison DA, Crocker PR, Banim S, et al. Silica stones in the urinary bladder. Lancet 1982; I(8274): 704–5CrossRef
161.
Farrer JH, Rajfer J. Silicate urolithiasis. J Urol 1984; 132(4): 739–40PubMed
162.
Irisawa C, Suzuki K, Nakagawa H, et al. Silicate urolithiasis: a case report [in Japanese]. Hinyokika Kiyo 1991; 37(3): 267–71PubMed
163.
Irani J, Doré B, Bon D, et al. Silica urinary calculi: report of a case [in French]. Prog Urol 1992; 2(2): 290–3PubMed
164.
Cruz Guerra NA, Gomez Garcia MA, Lovaco Castellano F, et al. Silica urolithiasis: report of a new case [in Spanish]. Actas Urol Esp 2000; 24(2): 202–4PubMed
165.
Augusti M, Mikaelian JC, Monsaint H, et al. A silica urinary calculus secondary to the absorption of gelopectose in a child [in French]. Prog Urol 1993; 3(5): 812–5PubMed
166.
Page RC, Heffner RR, Frey A. Urinary excretion of silica in humans following oral administration of magnesium trisilicate. Am J Dig Dis 1941; 8(1): 13–5CrossRef
167.
Bailey CB. Silica excretion in cattle fed a ration predisposing to silica urolithiasis: total excretion and diurnal variations. Am J Vet Res 1967; 28(127): 1743–9PubMed
168.
Gutierrez C, Padron M, Banares A, et al. Urinary retention in two male dromedaries due to silica uroliths. Zentralbl Veterinarmed A 1999; 46(9): 523–6PubMed
169.
Osborne CA, Hammer RF, Klausner JS. Canine silica urolithiasis. J Am Vet Med Assoc 1981; 178(8): 809–13PubMed
170.
Manning RA, Blaney BJ. Identification of uroliths by infrared spectroscopy. Aust Vet J 1986; 63(12): 393–6PubMed
171.
Forman SA, Whiting F, Connell R. Silica urolithiasis in beef cattle: 3. chemical and physical composition of the uroliths. Can J Comp Med 1959; 23(4): 157–62PubMed
172.
Bailey CB. The precipitation of polymerized silicic acid by urine protein: a possible mechanism in the etiology of silica urolithiasis. Can J Biochem 1972; 50(3): 305–11PubMedCrossRef
173.
Aldrich J, Ling GV, Ruby AL, et al. Silica-containing urinary calculi in dogs (1981–1993). J Vet Intern Med 1997; 11(5): 288–95PubMedCrossRef
174.
Singh SV, Khan MF, Rahman Q. Interaction of silica with plasma proteins: in vivo studies. Toxicol Letters 1985; 28(2-3): 89–92CrossRef
175.
Emerick RJ. Phosphate inhibition of protein-polysilicic acid complex formation in vitro: a factor in preventing silica urolithiasis. J Nutr 1987; 117(11): 1924–28PubMed
176.
AngwafoIII FF, Daudon M, Wonkam A, et al. Pediatric urolithiasis in sub-Saharan Africa: a comparative study in two regions of Cameroon. Eur Urol 2000; 37: 106–11PubMedCrossRef
177.
178.
Sabot JF, Bornet CE, Favre S, et al. The analysis of peculiar urinary (and other) calculi: an endless source of challenge. Clin Chim Acta 1999; 283(1–2): 151–8PubMedCrossRef
179.
Alpaugh HB, Johnson FB. Silicon dioxide calculi in humans in the absence of silicate antacid medication. Scan Electron Microsc 1986; Pt (2): 969–72
180.
Gaultier M, Bismuth C, Efthymiou ML, et al. Néphropathie tubulo-interstitielle aiguë au cours d’une intoxication par la glafénine [letter]. Nouv Presse Med 1975; 1: 3125
181.
Réveillaud RJ, Daudon M, Protat MF, et al. Renal pelvis stones made of glafenic acid in two patients under prolonged treatment with analgesics (author’s translation) [in French]. Nephrologie 1980; 1(1): 3–8PubMed
182.
Daudon M, Protat MF, Réveillaud RJ. Renal toxicity of glafenine in man: renal stones and acute renal failure [in French]. Ann Biol Clin (Paris) 1983; 41(2): 105–11
183.
Pasquier B, Griffa N, Heritier P, et al. Urinary calculi caused by glaphenine: role of radiology in diagnosis: apropos of a case [in French]. J Radiol 1989; 70(6–7): 423–5PubMed
184.
Moesch C, Daudon M, Leymarie J, et al. Glaphenine-containing gallstones. Eur J Chem Clin Biochem 1993; 31(5): 329–33
185.
Daudon M, Moesch C, Marty L, et al. Antrafénine: calculs urinaires et cristalluries. Thérapie 1986; 41: 499–504PubMed
186.
Moesch C, Rincé M, Raby C, et al. Identification d’un metabolite de la floctafénine dans un calcul urinaire. Ann Biol Clin (Paris) 1987; 45: 546–50
187.
Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med 1975; 292(12): 626–7PubMedCrossRef
188.
Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med 1969; 280(8): 426–7PubMedCrossRef
189.
Sperling O, Brosh S, Boer P, et al. Urinary xanthine stones in an allopurinol-treated gouty patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Isr J Med Sci 1978; 14(2): 288–92PubMed
190.
Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol 1983; 130(1): 157–9PubMed
191.
Loris Pablo C, Olivan del Cacho MJ, Heras Gironella M, et al. Xanthine lithiasis in a case of Lesch-Nyhan syndrome treated with allopurinol [in Spanish]. An Esp Pediatr 1983; 19(5): 401–4PubMed
192.
Kranen S, Keough D, Gordon RB, et al. Xanthine-containing calculi during allopurinol therapy. J Urol 1985; 133(4): 658–9PubMed
193.
Oka T, Utsunomiya M, Ichikawa Y, et al. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int 1985; 40(3): 138–40PubMedCrossRef
194.
Volpe P, Peyrottes A, Lammle M, et al. Calcul urinaire de xanthine chez un patient porteur d’un syndrome de Lesh Nyhan: a propos d’un cas. Prog Urol 1997; 7(1): 74–7PubMed
195.
Stote RM, Smith LH, Dubb JW, et al. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy. Ann Intern Med 1980; 92(3): 384–5PubMed
196.
Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 1987; 33(12): 2314–6PubMed
197.
Rincé C, Daudon M, Moesch C, et al. Identification of flumequine in a urinary calculus. J Clin Chem Clin Biochem 1987; 25: 313–4PubMed
198.
Cifuentes I, Bellanato J, Arquillué A, et al. Presencia de acido oxolinico en un calculo renal. Arch Esp Urol 1986; 39(5): 369–73PubMed
199.
Daudon M, Réveillaud RJ, Laurence C, et al. Drug-induced oxolinic acid crystalluria and nephrolithiasis [letter]. Clin Nephrol 1987; 28(3): 156PubMed
200.
Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000; 164(2): 438PubMedCrossRef
201.
Najjar MF, Rammah M, Oueslati A, et al. Apport de la spectrophotométrie infrarouge dans l’analyse des calculs urinaires. Le Biologiste 1988; 22: 215–20
202.
Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant 1990; 5(11): 974–6PubMedCrossRef
203.
Dulac Y, Bouissou F, Azéma C, et al. Anuria caused by urinary lithiasis induced by ceftriaxone in a 6-year-old child [in French; letter]. Presse Med 1995; 24(19): 916PubMed
204.
Feher G, Benczik A, Szabo E, et al. Renal gravel formation inducing renal insufficiency as a side-effect of ceftriaxon [in Hungarian]. Orv Hetil 1999; 140(14): 769–71PubMed
205.
de Moor RA, Egberts AC, Schroder CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999; 158(12): 975–7PubMedCrossRef
206.
Mulvaney WP, Beck CW, Brown RR. Urinary phenazopyridine stones: a complication of therapy. JAMA 1972; 221: 1511–2PubMedCrossRef
207.
Crawford ED, Mulvaney WP. Rapid increase in calculous size: a possible hazard of phenazopyridine hydrochloride therapy in the presence of already formed stones. J Urol 1978; 119(2): 280–1PubMed
208.
Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988; II(8625): 1411–3CrossRef
209.
Lopez AJ, O’Keefe P, Morrissey M, et al. Ceftriaxone-induced cholelithiasis. Ann Intern Med 1991; 115(9): 712–4PubMed
210.
Kearney DK, O’Donnell D. Iatrogenic gallstones: a ceftriaxone complication. Australas Radiol 1998; 42: 236–7PubMedCrossRef
211.
Ko CW, Sekijima JH, Lee SP. Biliary sludge. Ann Intern Med 1999; 130 Pt 1: 301–11
212.
213.
Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986; 32: 408–17PubMedCrossRef
214.
Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 1988; 34: 256–60PubMedCrossRef
215.
Rippelmeyer DJ, Synhavsky A. Ciprofloxacin and allergic interstitial nephritis [letter]. Ann Intern Med 1988; 109: 170PubMed
216.
Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32(2): 75–8PubMed
217.
Allon M, Lopez EJ, Min KW. Acute renal failure due to ciprofloxacin. Arch Intern Med 1990; 150: 2187–9PubMedCrossRef
218.
Schlüter G. Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987; 82 Suppl. 4A: 91–3
219.
Zupancic M, Bukovec P. Complexation of magnesium (II) with ciprofloxacin and norfloxacin. Act Pharm 1996; 46: 221–8
220.
Swanson BN, Boppana VK, Vlasses PH, et al. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983; 23(2): 284–8PubMedCrossRef
221.
Moesch C, Rincé M, Raby C, et al. Aminopenicillin crystalluria: identification by infrared spectrophotometry [in French]. Ann Biol Clin (Paris) 1985; 43(3): 227–31
222.
Boffa JJ, De Preneuf H, Bouadma L, et al. Acute renal failure after amoxicillin crystallization [in French]. Presse Med 2000; 29(13): 699–701PubMed
223.
Boursas M, Benhassine L, Kempf J, et al. Obstructive renal insufficiency caused by amoxicillin crystalluria [in French]. Ann Fr Anesth Reanim 1997; 16(7): 908–10PubMedCrossRef
224.
Fogazzi GB, Cantu M, Saglimbeni L, et al. Amoxycillin, a rare but possible cause of crystalluria. Nephrol Dial Transplant 2003; 18(1): 212–4PubMedCrossRef
225.
Menzi P. Furadantin-Stein in einer Ureterozele. Helvet Chir 1970; 37(4/5): 538–40
226.
MacDonald JB, MacDonald ET. Nitrofurantoin crystalluria. BMJ 1976 Oct 30; II: 1044–5CrossRef
227.
Pickens CL, Milliron AR, Fussner AL, et al. Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Urology 1999; 54(1): 23–7PubMedCrossRef
228.
Assimos DG, Langenstroer P, Leinbach RF, et al. Guaifenesin-and ephedrine-induced stones. J Endourol 1999; 13(9): 665–7PubMedCrossRef
229.
Blau JJ. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol 1998; 160 (3 Pt 1): 825PubMedCrossRef
230.
Powell T, Hsu FF, Turk J, et al. Ma-Huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 1998; 32(1): 153–9PubMedCrossRef
231.
Cate IV JC, Tenser R. Acute primidone overdose with massive crystalluria. Clin Toxicol 1975; 8(4): 385–9PubMedCrossRef
232.
Lehmann DF. Primidone crystalluria following overdose: a report of a case and an analysis of the literature. Med Toxicol Adverse Drug Exp 1987; 2(5): 383–7PubMedCrossRef
233.
Pitman SW, Frei E. Weekly methotrexate-calcium leukovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep 1977; 61: 695–701PubMed
234.
Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981; 19: 453–6PubMedCrossRef
235.
Garnick MB, Mayer RJ, Abelson HT. Acute renal failure associated with cancer treatment. In: Brenner BM, Lazarus JM, editors. Acute renal failure. 2nd ed. New York: Churchill Livingstone, 1988: 636–45
236.
Lenk S, Brien G, Bick C. Harnsteinbildung durch Dihydrotachysterol-Uberdosierung. Z Arztl Forbild 1970; 9: 470–1
237.
Taylor WH. Renal calculi and self-medication with multivitamin preparations containing vitamin D. Clin Sci 1972; 42: 515–22PubMed
238.
Pak CYC. Nephrolithiasis from calcium supplementation. J Urol 1987; 137: 1212–3PubMed
239.
Jones G, Hogan DB, Yent DB, et al. Prevention and management of osteoporosis: consensus statements from scientific Advisory Board of the Osteoporosis Society of Canada. 8: vitamin D metabolites and analogs in the treatment of osteoporosis. CMAJ 1996; 155: 955–61
240.
Oreopoulos DG, Silverberg S. Calcium oxalate urinary-tract stones in patients on maintenance dialysis. N Engl J Med 1974; 290(25): 1438–9PubMed
241.
Caralps A, Lloveras J, Andreu J, et al. Urinary calculi in chronic dialysis patients. Lancet 1979; II(8150): 1024–5CrossRef
242.
Oren A, Husdan H, Chen PT, et al. Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25(3): 534–8PubMedCrossRef
243.
Daudon M, Lacour B, Jungers P, et al. Urolithiasis in patients with end-stage renal failure. J Urol 1992; 147: 977–80PubMed
244.
Kass M, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophtalmology 1981; 88: 261–5
245.
Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996; 15(6): 378–93PubMedCrossRef
246.
Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17(6): 441–52PubMedCrossRef
247.
Persky L, Chambers D, Potts A. Calculus formation and ureteral colic following acetazolamide therapy. JAMA 1956; 161: 1625–6CrossRef
248.
Barraquer J, Escribano J. Colicos renales en el curso de tratamientos con acetazolamide. Rev Clin Esp 1957; 64: 310–3PubMed
249.
Parfitt AM. Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis; relationship to citrate and calcium excretion. Arch Intern Med 1969; 124(6): 736–40PubMedCrossRef
250.
Pepys MB. Acetazolamide and renal stone formation [letter]. Lancet 1970; I(7651): 837CrossRef
251.
Parfitt AM. Acetazolamide and renal stone formation [letter]. Lancet 1970; II(7664): 153CrossRef
252.
Roise O, Otnes B. Acetazolamide and renal calculi [in Norwegian]. Tidsskr Nor Laegeforen 1986; 106(1): 25–6PubMed
253.
Rivalan J, Chevet D, Le Pogamp P, et al. Renal lithiasis, a logical complication of long-term treatment of glaucoma with a carbonic anhydrase inhibitor [in French]. Ann Med Interne (Paris) 1989; 140(5): 419–20
254.
Tawil R, Moxley III RT, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43(6): 1105–6PubMedCrossRef
255.
256.
Carlsen J, Durcan J, Zabriskie N, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117(8): 1087–8PubMedCrossRef
257.
Wallace MR, MacDiarmid J, Reeder J. Exacerbation of nephrolithiasis by a carbonic anhydrase inhibitor. N Z Med J 1974; 79(509): 687–90PubMed
258.
Resor Jr SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990; 40(11): 1677–81PubMedCrossRef
259.
260.
Libenson MH, Kaye EM, Rosman NP, et al. Acetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn. Pediatr Neurol 1999; 20(3): 185–91PubMedCrossRef
261.
Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21: 225–8PubMedCrossRef
262.
Paisley KE, Tomson CR. Calcium phosphate stones during long-term acetazolamide treatment for epilepsy. Postgrad Med J 1999; 75(885): 427–8PubMed
263.
Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35(4): 241–56PubMedCrossRef
264.
Natsch S, Hekster YA, Keyser A, et al. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997; 17(4): 228–40PubMedCrossRef
265.
266.
Saito Y, Yanagaki S, Oguni H, et al. Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy [in Japanese]. No To Hattatsu 2002; 34(5): 415–20PubMed
267.
Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 Suppl. 2: S18–22PubMedCrossRef
268.
Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 1998; 55(6): 554–62PubMed
269.
Takhar J, Manchanda R. Nephrolithiasis on topiramate therapy. Can J Psychiatry 2000; 45(5): 491–3PubMed
270.
Daudon M, Réveillaud RJ, Rod D, et al. Piridoxilate-induced calcium oxalate nephrolithiasis: a nation-wide epidemiologic evaluation of incidence. In: Walker VR, Sutton RAL, Cameron ECB, et al., editors. Urolithiasis. New York: Plenum Press, 1989: 677–9
271.
Daudon M, Réveillaud RJ, Jungers P. Piridoxilate-associated calcium oxalate urinary calculi: a new metabolic drug-induced nephrolithiasis [letter]. Lancet 1985; I(8441): 1338CrossRef
272.
Wolf C, Maistre-Charransol G, Barthélémy C, et al. Iatrogenic oxalic lithiasis caused by piridoxilate [in French]. Nephrologie 1985; 6(5): 225–7PubMed
273.
Vigeral P, Kenouch S, Chauveau D, et al. Piridoxilate-associated nephrocalcinosis: a new form of chronic oxalate nephropathy. Nephrol Dial Transplant 1987; 2(4): 275–8PubMed
274.
Dequiedt P, Gosselin B, Benoit O, et al. Acute renal failure caused by acute oxalosis after massive ingestion of piridoxilate [in French]. Nephrologie 1985; 6(5): 228–30PubMed
275.
Mousson C, Justrabo E, Rifle G, et al. Piridoxilate-induced oxalate nephropathy can lead to end-stage renal failure. Nephron 1993; 63(1): 104–6PubMedCrossRef
276.
Hufnagle KG, Khan SN, Penn D, et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 1982; 70(3): 360–3PubMed
277.
Venkataraman PS, Han BK, Tsang RC, et al. Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy. Am J Dis Child 1983; 137(12): 1157–61PubMed
278.
Glasier CM, Stoddard RA, Ackerman Jr NB, et al. Nephrolithiasis in infants: association with chronic furosemide therapy. Am J Roentgenol 1983; 140(1): 107–8
279.
Noe HN, Bryant JF, Roy III S, et al. Urolithiasis in pre-term neonates associated with furosemide therapy. J Urol 1984; 132(1): 93–4PubMed
280.
Gilsanz V, Fernal W, Reid BS, et al. Nephrolithiasis in premature infants. Radiology 1985; 154(1): 107–10PubMed
281.
Myracle MR, McGahan JP, Goetzman BW, et al. Ultrasound diagnosis of renal calcification in infants on chronic furosemide therapy. J Clin Ultrasound 1986; 14(4): 281–7PubMedCrossRef
282.
Ezzedeen F, Adelman RD, Ahlfors CE. Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr 1988; 113(3): 532–9PubMedCrossRef
283.
Itami N, Kawaguti M, Akutsu Y, et al. Renal calcifications in preterm infants [letter]. J Pediatr 1989; 114(6): 1068PubMed
284.
Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994; 125(1): 149–51PubMedCrossRef
285.
Blickman JG, Herrin JT, Cleveland RH, et al. Coexisting nephrolithiasis and cholelithiasis in premature infants. Pediatr Radiol 1991; 21(5): 363–4PubMedCrossRef
286.
287.
Saarela T, Lanning P, Koivisto M, et al. Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up. Eur J Pediatr 1999; 158: 668–72PubMedCrossRef
288.
Kim YG, Kim B, Kim MK, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant 2001; 16: 2303–9PubMedCrossRef
289.
Levine DZ, Roy D, Tolnai G, et al. Chloride depletion and nephrocalcinosis. Am J Physiol 1974; 227: 878–83PubMed
290.
Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352: 1026–9PubMedCrossRef
291.
Sidhu H, Schmidt ME, Cornelius JG, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999; 10: S334–40PubMed
292.
Hokama S, Honma Y, Toma C, et al. Oxalate-degrading Enterococcus faecalis. Microbiol Immunol 2000; 44: 235–40PubMed
293.
Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001; 60: 1097–105PubMedCrossRef
294.
Golematis B, Hatzitheofilou C, Dreiling DA, et al. The incidence of urolithiasis in pepticulcer patients. Am J Gastroenterol 1977; 68: 367–71PubMed
295.
Robson RH, Heading RC. Obsolete but dangerous antacid preparations. Postgrad Med J 1978; 54: 36–7PubMedCrossRef
296.
Bloom WK, Flinchum D. Osteomalacia with pseudofractures caused by the ingestion of aluminum hydroxyde. JAMA 1960; 174: 1327–30CrossRef
297.
Dent CE, Winter CS. Osteomalacia due to phosphate depletion from excess aluminum hydroxide ingestion. BMJ 1974; 1: 551–2PubMedCrossRef
298.
Baker LR, Ackrill P, Cattel WR, et al. Iatrogenic osteomalacia and myopathy dueto phosphate depletion. BMJ 1974; 3: 150–2PubMedCrossRef
299.
Cooke N, Teitelbaum S, Avioli LV. Antacid-induced osteomalacia and nephrolithiasis. Arch Intern Med 1978; 138: 1007–9PubMedCrossRef
300.
Millette CH, Snodgrass GL. Acute renal failure associated with chronic antacid ingestion. Am J Hosp Pharm 1981; 38(9): 1352–5PubMed
301.
Malek RS, Kelalis PP. Pediatric nephrolithiasis. J Urol 1975; 113: 545–51PubMed
302.
Howard SC, Kaplan SD, Razzouk BI, et al. Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia 2003; 17(3): 541–6PubMedCrossRef
303.
Kamitsuka MD, Williams MA, Nyberg DA, et al. Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia. J Perinatal 1995; 15(5): 359–63
304.
Kumar N, Khwaja GA, Gupta M, et al. Antiepileptic drug induced osteomalacic myopathy with hyperparathyroidism and nephrolithiasis. J Assoc Physicians India 1993; 41(11): 748–9PubMed
305.
Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147: 1215–8PubMed
306.
Smith LH. Risk of oxalate stone from large doses of vitamin C [letter]. N Engl J Med 1978; 298: 856
307.
Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998; 28(9): 695–700PubMedCrossRef
308.
Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003; 170 (2 Pt 1): 397–401PubMedCrossRef
309.
Chalmers AH, Cowley DM, Brown JM. A possible etiological role for ascorbate in calculi formation. Clin Chem 1986; 32(2): 333–6PubMed
310.
Curhan GC, Willett WC, Rimm EB, et al. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 1996; 155: 1847–51PubMedCrossRef
311.
Curhan GC, Willett WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999; 10(4): 840–5PubMed
312.
Moesch C, Rincé M, Daudon M, et al. Renal intratubular crystallization of calcium oxalate and naftidrofuryl oxalate. Lancet 1991; 338: 1219–20PubMedCrossRef
313.
Moesch C, Charmes JP, Bouthier F, et al. Calcium oxalate crystalluria in elderly patients and treatment with naftidrofuryl oxalate. Age Ageing 1995; 24(6): 464–7PubMedCrossRef
314.
Retornaz F, Jean-Pastor MJ, Monestier S, et al. Recurrent calcium oxalate nephrolithiasis induced by naftidrofuryl oxalate [letter]. Nephron 2000; 85(1): 92PubMedCrossRef
315.
Van der Niepen P, Janssen van Doorn K, Van den Houte K, et al. Nimesulide and acute renal failure caused by oxalate precipitation. Nephrol Dial Transplant 2002; 17: 315–22PubMedCrossRef
316.
Thomas DW, Edwards JB, Gilligan JE, et al. Complications following intravenous administration of solutions containing xylitol. Med J Aust 1972; 1: 1238–46PubMed
317.
Evans GW, Philips G, Mukherjee TM, et al. Identification of crystals deposited in brain and kidney after xylitol administration by biochemical, histochemical, and electron diffraction methods. J Clin Path 1973; 26: 32–6PubMedCrossRef
318.
Dolp R, Paulini K. Oxalate formation by polytraumatized patients after parenteral nutrition with amino acids and xylitol [in German]. Int Z Vitam Ernahrungsforsch Beih 1976; 15: 228–33PubMed
319.
Ludwig B, Schindler E, Bohl J, et al. Reno-cerebral oxalosis induced by xylitol. Neuroradiology 1984; 26: 517–21PubMedCrossRef
320.
Frydl V. Cerebrorenal oxalate formation: a metabolic abnormality following parenteral infusions of carbohydrate exchange substances [in German]. Zentralbl Allg Pathol 1987; 133(4): 369–76PubMed
321.
Dick WH, Lingeman JE, Preminger GM, et al. Laxative abuse as a cause for ammonium urate renal calculi. J Urol 1990; 143(2): 244–7PubMed
322.
Soble JJ, Hamilton BD, Streem SB. Ammonium acid urate calculi: a reevaluation of risk factors. J Urol 1999; 161(3): 869–73PubMedCrossRef
323.
Navas P, Grasset D. Anurie par lithiase urétérale urique bilatérale au cours d’un traitement par l’Amplivix. J Urol Néphrol 1973; 79: 466–9
324.
Matzkies F. Wirkungen und Nebenwirkungen von Benz-bromaron bei der Initialbehandlung von Hyperurikämie und Gicht. Ergebnisse eines Feldversuches mit 3899 Patienten. Fortschr Med 1978; 96(32): 1619–21
325.
McLain DA, Garriga FJ, Kantor OS. Adverse reactions associated with ticrynafen use. JAMA 1980; 243(8): 763–4PubMedCrossRef
326.
Paddack GL, Wahl RC, Holman RE, et al. Acute renal failure associated with ticrynafen. JAMA 1980; 243(8): 764–5PubMedCrossRef
327.
Richard O, Toupance O, Hublot C, et al. Factors affecting urinary lithogenesis following tienilic acid administration in man [in French]. Therapie 1981; 36(4): 429–34PubMed
328.
Pfister B, Imhof P, Wirz H. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol 1978; 13(4): 263–5PubMedCrossRef
329.
Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84(1): 153–6PubMedCrossRef
330.
Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3(1): 29–35PubMedCrossRef
Metadata
Title
Drug-Induced Renal Calculi
Epidemiology, Prevention and Management
Authors
Dr Michel Daudon
Paul Jungers
Publication date
01-02-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464030-00003

Other articles of this Issue 3/2004

Drugs 3/2004 Go to the issue

Adis Drug Evaluation

Epoetin Beta

Current Opinion

Regional Anaesthesia in Pre-eclampsia

Review Article

Contemporary Pharmacological Manipulation in Assisted Reproduction

Therapy In Practice

Primary Blepharospasm

Review Article

The Role of Proton Pump Inhibitors in Gastro-oesophageal Reflux Disease